NEXICLON XR Drug Patent Profile

Which patents cover Nexiclon Xr, and what generic alternatives are available?

Nexiclon Xr is a drug marketed by Rosemont and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in NEXICLON XR is clonidine. There are twenty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nexiclon Xr

A generic version of NEXICLON XR was approved as clonidine by MYLAN TECHNOLOGIES on July 16^th, 2010.

Summary for NEXICLON XR

International Patents:	21
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NEXICLON XR

NEXICLON XR is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rosemont	NEXICLON XR	clonidine	TABLET, EXTENDED RELEASE;ORAL	022500-001	Dec 3, 2009		RX	No	No			Y
Rosemont	NEXICLON XR	clonidine	TABLET, EXTENDED RELEASE;ORAL	022500-002	Dec 3, 2009		DISCN	No	No			Y
Rosemont	NEXICLON XR	clonidine	TABLET, EXTENDED RELEASE;ORAL	022500-001	Dec 3, 2009		RX	No	No			Y

International Patents for NEXICLON XR

See the table below for patents covering NEXICLON XR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E536867
Australia	2007227569	Modified release formulations containing drug-ion exchange resin complexes
Brazil	PI0709606	suspensão líquida administrável oralmente com características de liberação modificada

NEXICLON XR Investment Scenario and Patent/Exclusivity Fundamentals (Revenue, Generics Risk, and Litigation Exposure)

Last updated: July 17, 2026

NEXICLON XR is an extended-release formulation of clonidine for ADHD. The investment case turns on (1) remaining exclusivity and patent barriers versus authorized generics and Paragraph IV filings, (2) payer and channel stickiness versus competing ADHD agents, and (3) exposure from any Orange Book-listed patents or method-of-use/formulation claims tied to the XR profile.

Because Nexiclon XR’s value is driven by US regulatory status and US patent/Orange Book listings, an investment-grade fundamentals analysis must anchor on: (a) the Orange Book patent list for the specific NDA strength and dosage form, (b) the associated FDA exclusivity (if any), (c) patent expiration and any pediatric exclusivity adjustments, and (d) whether any ANDA/Paragraph IV challenges have been filed and litigated.

No complete, citable dataset is available in the provided context to produce an accurate exclusivity and patent timeline, litigation docket summary, or current revenue baselines for Nexiclon XR. Under the operating constraints, this prevents a complete and accurate response.